Feb 25, 2021 / 02:50PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
Okay. Great. Well, thank you, everyone, for joining us. I'm Patrick Donnelly, the tools and diagnostics analyst here at Citi. Happy to have Chuck Kummeth, the CEO of Bio-Techne; and Jim Hippel, the CFO.
It's going to be a Q&A. So if you have any questions, feel free to e-mail me. And Chuck, I know you wanted to start off with a few slides. So I'll turn it over to you.
Charles R. Kummeth - Bio-Techne Corporation - CEO, President & Director
Okay. I'll wait for David, to get them up here and all right. Over the next slide. I'm just going to spend a few minutes.
So just a few slides for any journalists online or people who don't know our story. So first off, with the safe harbor, I won't spend any time. You've seen this before, but of course, we have to show it.
Next slide. Bio-Techne is a 43 year old company. We're fiscal, we end in June. So as of last year, we were at $739 million. We're well north $800 million this year and climbing. We're
Bio-Techne Corp at Citi Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Transcript
Feb 25, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers